Volume 62, Issue 3, Pages (September 2012)

Slides:

Advertisements

Similar presentations

Volume 50, Issue 3, Pages (September 2006)

Advertisements

Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Management of Acute and Chronic Retention in Men

Volume 54, Issue 6, Pages (December 2008)

Volume 72, Issue 5, Pages (November 2017)

Debra E. Irwin, Ian Milsom, Zoe Kopp, Paul Abrams European Urology

Volume 64, Issue 2, Pages (August 2013)

Volume 66, Issue 3, Pages (September 2014)

Volume 50, Issue 5, Pages (November 2006)

Volume 59, Issue 4, Pages (April 2011)

Volume 52, Issue 2, Pages (August 2007)

Let the Games Begin (with EAU Approval)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 70, Issue 5, Pages (November 2016)

Volume 45, Issue 4, Pages (April 2004)

Volume 57, Issue 5, Pages (May 2010)

Volume 53, Issue 2, Pages (February 2008)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 52, Issue 3, Pages (September 2007)

Volume 54, Issue 4, Pages (October 2008)

Volume 56, Issue 3, Pages (September 2009)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 3, Pages (September 2016)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Volume 68, Issue 3, Pages (September 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 1, Pages (July 2011)

Volume 55, Issue 3, Pages (March 2009)

Volume 72, Issue 3, Pages (September 2017)

Volume 52, Issue 4, Pages (October 2007)

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 6, Pages (June 2012)

Volume 69, Issue 2, Pages (February 2016)

Volume 65, Issue 2, Pages (February 2014)

Volume 61, Issue 5, Pages (May 2012)

Volume 58, Issue 5, Pages (November 2010)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Classification of Male Lower Urinary Tract Symptoms Using Mathematical Modelling and a Regression Tree Algorithm of Noninvasive Near-Infrared Spectroscopy.

The Economic Costs of Overactive Bladder in Germany

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 52, Issue 4, Pages (October 2007)

Volume 62, Issue 3, Pages (September 2012)

Volume 50, Issue 5, Pages (November 2006)

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials David Moher, MSc, Kenneth F Schulz,

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Hooman Djaladat, Parvin Tajik, Pooya Payandemehr, Sara Alehashemi

Volume 74, Issue 5, Pages (November 2018)

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Testicular Cancer Variations in Time and Space in Europe

Volume 72, Issue 2, Pages (August 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 53, Issue 6, Pages (June 2008)

European Urology is “Your” Journal

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Volume 55, Issue 3, Pages (March 2009)

Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies David A. Ginsberg, MD, Lynne Kolton.

Profile of Silodosin European Urology Supplements

Volume 52, Issue 6, Pages (December 2007)

Volume 53, Issue 2, Pages (February 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 62, Issue 3, Pages 507-514 (September 2012) Botulinum Toxin A Versus Placebo for Refractory Detrusor Overactivity in Women: A Randomised Blinded Placebo-Controlled Trial of 240 Women (the RELAX Study) Douglas G. Tincello, Sara Kenyon, Keith R. Abrams, Christopher Mayne, Philip Toozs-Hobson, David Taylor, Mark Slack European Urology Volume 62, Issue 3, Pages 507-514 (September 2012) DOI: 10.1016/j.eururo.2011.12.056 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials diagram. DO=detrusor overactivity; ISC=intermittent self-catheterisation. Figures in square brackets are the number of women returning diary data “in window”; numbers in curved brackets are cumulative totals of number of patients lost to follow-up or withdrawn at each visit. European Urology 2012 62, 507-514DOI: (10.1016/j.eururo.2011.12.056) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Outcome data at 6 mo. onaBoNTA=botulinum toxin A. European Urology 2012 62, 507-514DOI: (10.1016/j.eururo.2011.12.056) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Time to patient-reported recurrence of symptoms. onaBoNTA=botulinum toxin A. European Urology 2012 62, 507-514DOI: (10.1016/j.eururo.2011.12.056) Copyright © 2012 European Association of Urology Terms and Conditions